快速查找

Global
吉凯基因 新药研发
吉凯基因 新药研发

新药研发聚焦于细胞治疗、基因治疗、抗体药物等创新药物的开发，致力于与临床医生共同将具有重大临床意义的科学研究进行临床转化，开发能够解决临床迫切需求的治疗产品。

目前已经建立起包含CAR-T、TCR-T等细胞治疗项目，AAV基因治疗项目以及单克隆抗体项目在内的完整的开发管线，并与多名领域带头人签署了长期的深度合作协议。

研发管线

Program Indication
Target
Validation Lead Candidate IIT** IND
Program：GB5005 Indication：Leukemia/Lymphoma

phase：IND

Program：GB5010 Indication：Multiple Myeloma

phase：IIT**

Program：*GB3010 Indication：Pancreatic Cancer

phase：Candidate

Program：GB3015 Indication：Nasopharyngeal Carcinoma

phase：Candidate

Program：GB7008 Indication：Ovarian Cancer

phase：Candidate

Program：*GB7001 Indication：Gastric Cancer

phase：Candidate

Program：GB3007 Indication：Synovial Sarcoma

phase：Candidate

Program：GB70041 Indication：Gastric Cancer

phase：Candidate

Program：GB7012 Indication：Colon Cancer

phase：Candidate

Program Indication
Target
Validation Lead Candidate IIT** IND
Program：GB5001 Indication：Leukemia/Lymphoma

phase：IIT**

Program：GB7004 Indication：Gastric Cancer

phase：Candidate

Program：GB5013 Indication：Colon Cancer

phase：Candidate

Program：GB7002 Indication：Solid Tumor

phase：Candidate

Program：GB5012 Indication：Colon Cancer

phase：Candidate

Program：GB7005 Indication：Blood Cancer

phase：Candidate

*First in class

**IIT (investigator-initiated trial) is optional not mandatory, and it serves as early evidence for safety and potentially efficacy for the individual programs.

合作伙伴